On 3 September, Novo Nordisk and the Indonesian Ministry of Health launched a joint platform to guide efforts to address the rising prevalence of diabetes and its associated costs. The platform is built on the findings from Novo Nordisk’s Blueprint for Change case on diabetes in the Indonesian society and its implications for action.